DexCom (DXCM)
(Delayed Data from NSDQ)
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden
by Zacks Equity Research
Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.
Veeva Systems (VEEV) Beats on Q3 Earnings, Revises FY24 Outlook
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both segments.
Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay
by Zacks Equity Research
Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing
by Zacks Equity Research
OrthoPediatrics (KIDS) continues to diversify its non-surgical offerings with the introduction of the DF2 Brace.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and a favorable liquidity structure.
Tandem Diabetes (TNDM) Launches Dexcom G7 Integrated t:slim X2
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.
Is DexCom (DXCM) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
DexCom (DXCM) possesses solid growth attributes, which could help it handily outperform the market.
3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail
by Zacks Equity Research
Omnicell (OMCL) accelerates a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service and Central Pharmacy Dispensing Services.
HealthEquity (HQY) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the third quarter of fiscal 2024.
Neogen (NEOG) to Offer Biosecurity Products With New Pact
by Zacks Equity Research
Neogen will be able to highlight its biosecurity and horse health products, like the COMPANION range of cleansers and disinfection solutions, through the latest collaboration.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) on global expansion and strategic alliance.
West Pharmaceutical's (WST) New Launch to Expand Portfolio
by Zacks Equity Research
West Pharmaceutical's (WST) latest addition to its portfolio is likely to address the critical need for more drug preparation and delivery options at the point of care.
Why You Should Retain UnitedHealth Group (UNH) Stock Now
by Zacks Equity Research
Growing membership, expanding government business, strategic acquisitions, improving operating margin and solid growth outlook poise UnitedHealth Group (UNH) well for growth.
Integra Gains From New Product Launches, Mounting Costs Ail
by Zacks Equity Research
Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.
Boston Scientific (BSX) Gains From Global Expansion, FX Woe Ails
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg benefits from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Henry Schein's (HSIC) Zahn Dental and Myerson Enter New Deal
by Zacks Equity Research
Henry Schein's (HSIC) dental laboratory business, Zahn Dental, is set to exclusively distribute Myerson's New Trusana 3D Premium Denture System.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.
Community Health (CYH) Sells Three Florida Facilities for $294M
by Zacks Equity Research
Community Health (CYH) divests three hospitals in Florida to Tampa General Hospital, substantiating its endeavor to intensify its focus on high-growth business areas.
Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments.
Thermo Fisher (TMO) Advances Health Equity via New Partnership
by Zacks Equity Research
Thermo Fisher (TMO) announces a collaboration with Project HOPE to improve health outcomes by enabling expanded access to HIV testing and support services in Nigeria.
BiomX (PHGE) Reports Positive Pulmonary Infection Treatment Data
by Zacks Equity Research
BiomX's (PHGE) BX004 showcases an impressive 14% conversion to a negative P. aeruginosa sputum culture at the end of treatment.
Nevro (NVRO) Up 15.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.